Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab
Zhang H, Luo W, Wang Y. Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab. Journal For ImmunoTherapy Of Cancer 2019, 7: 47. PMID: 30777137, PMCID: PMC6380028, DOI: 10.1186/s40425-019-0532-1.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsAntirheumatic AgentsChemical and Drug Induced Liver InjuryColitisColonDiarrheaHumansInfliximabIpilimumabLiverMaleNivolumabProstatic NeoplasmsConceptsImmune-related adverse reactionsGrade 3 colitisGastrointestinal reactionsLiver injuryClinical historyImmune checkpoint inhibitor-related colitisBackgroundImmune checkpoint inhibitorsElevated liver enzymesPD-1 inhibitorsTNF-α agentsAcute liver injuryInflammatory bowel diseaseOne-time infusionInfliximab therapyAcute hepatitisCheckpoint inhibitorsRescue therapyAdvanced malignanciesBiologic agentsBowel diseaseLiver profileCase presentationWePatient populationCTLA-4Final diagnosis